• Part of company’s €440 million investment in Ireland, strengthens Merck’s in-region-for-region supply resilience
• Merck’s first climate-neutral manufacturing facility, powered by 100 percent renewable electricity
• New Blarney site in Cork, Ireland expands filter manufacturing capacity, creating more than 200 jobs by 2028

The 3,000-square-meter cleanroom facility supports global demand for critical filtration products used in the manufacturing of vaccines and life-saving therapies, including monoclonal antibodies, and emerging modalities like cell and gene therapies. By localizing these capacities in Europe, Merck hopes to reduce cross-border dependencies for the company’s customers.

“Ireland is a leading hub for biopharmaceutical manufacturing and innovation for Europe and globally. By expanding manufacturing in Cork, we reinforce our in-region-for-region manufacturing and supply model, reducing cross-border risks and providing manufacturers with reliable access to critical filtration technologies they need to deliver life-changing therapies”, said Jean-Charles Wirth, Member of the Executive Board of Merck and CEO Life Science.

The facility is expected to begin production in the fourth quarter of 2025 and will manufacture filtration devices used in aseptic processing, tangential-flow filtration and virus filtration. These filtration technologies are key components of most bioprocessing templates and are vital to controlling bioburden, streamlining purification and removing viral contaminants. They assure vaccines and therapeutics meet expected purity standards and are safe for administration to patients.

The new site will run on 100% renewable electricity and an innovative heat recovery system, which is estimated to avoid up to 61 metric tons of CO2 equivalents annually. It will also reuse up to 95% of high-purity reverse osmosis water from its filtration manufacturing process.

The Blarney Business Park facility is part of Merck’s largest Life Science investment to date. Together with the nearby Carrigtwohill site, the company has committed €440 million to expand membrane and filtration manufacturing in Ireland. These investments are part of Merck’s €2 billion Life Science global expansion program, announced in 2020, to meet growing demand for life-saving therapies across Europe, China, and the United States.